Table 2 Clinicopathologic characteristics of castration-resistant prostate cancer patients, stratified by clinical trial participation
Overall (n = 299) | Clinical trial | |||
|---|---|---|---|---|
Participants (n = 65) | Non-participants (n = 234) | p | ||
Age | 66.5 (61.0–71.8) | 65.0 (62.0–71.0) | 67.0 (61.0–72.0) | 0.384 |
Body mass index | 23.1 (20.9–24.7) | 22.9 (21.3–24.7) | 23.4 (21.2–25.1) | 0.345 |
Laboratory valuesa | ||||
PSA (ng/mL) | 69.2 (15.0–182.0) | 25.8 (9.6–73.6) | 88.4 (18.0–247.3) | 0.005 |
Hemoglobin (g/dL) | 12.0 (10.7–13.0) | 12.4 (11.7–13.3) | 11.9 (10.4–12.9) | 0.514 |
Albumin (U/L) | 4.0 (3.7–4.4) | 4.3 (4.0–4.5) | 4.0 (3.7–4.3) | 0.001 |
ALP (U/L) | 109.0 (70.0–209.0) | 88.0 (67.0–133.5) | 118 (71.0–221.5) | 0.070 |
WBC count (× 109/L) | 5.8 (4.8–7.3) | 5.8 (4.7–7.3) | 5.8 (4.9–7.3) | 0.919 |
T stage | 0.764 | |||
≤ T2 | 187 (62.5%) | 42 (64.7%) | 145 (61.9%) | |
≥ T3 | 112 (37.5%) | 23 (35.3%) | 89 (38.1%) | |
N stage | 0.491 | |||
N0 | 127 (42.5%) | 30 (46.2%) | 97 (41.5%) | |
N1 | 172 (57.5%) | 35 (53.8%) | 137 (58.5%) | |
M stage | 1.000 | |||
M0 | 73 (24.4%) | 15 (23.1%) | 58 (24.8%) | |
M1 | 226 (75.6%) | 50 (76.9%) | 176 (75.2%) | |
Metastatic site | ||||
Bone | 166 (55.5%) | 37 (57.0%) | 129 (55.1%) | 0.856 |
Visceral | 8 (2.7%) | 8 (12.3%) | 0 (0.0%) | 0.215 |
Lymph node | 142 (47.5%) | 26 (40.0%) | 116 (49.6%) | 0.116 |
Gleason score | 0.267 | |||
≤ 7 | 156 (52.2%) | 30 (46.2%) | 126 (53.8%) | |
≥ 8 | 143 (47.8%) | 35 (53.8%) | 108 (46.2%) | |
CCI | 0.780 | |||
≤ 1 | 142 (%) | 32 (49.2%) | 110 (47.0%) | |
≥ 2 | 157 (%) | 33 (50.8%) | 124 (53.0%) | |
ECOG PS | 0.033 | |||
≤ 1 | 261 (87.3%) | 62 (95.4%) | 199 (85.1%) | |
≥ 2 | 38 (12.7%) | 3 (4.6%) | 35 (14.9%) | |
Primary treatmentb | ||||
Prostatectomy | 149 (49.8%) | 47 (72.3%) | 102 (43.6%) | < 0.001 |
Radiation therapy | 33 (11.0%) | 10 (15.4%) | 23 (9.8%) | 0.261 |